Descriptors
Documents disponibles dans cette catégorie (13)



Extend search on down-posting(s)
Adverse Effects of Vaccines : Evidence and Causality [printed text] / Kathleen Stratton, Author ; Andrew Ford, Author ; Erin Rusch, Author ; Ellen Wright Clayton, Author . - Washington, D.C. : National Academy Press, 2011 . - 800 p. : ill. ; A5.
ISBN : 978-0-309-21435-3 : $ 72,86
Languages : English (eng)
Descriptors: Indexation
Electronic books ; Encephalitis, Varicella Zoster ; Epidemiology ; Evidence-Based Practice ; Influenza Vaccines ; Papillomavirus Vaccines ; United States ; Vaccines
Classification
QW 805 Vaccines. Antitoxins. ToxoidsAbstract:
In 1900, for every 1000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The cornerstone of the vaccine safety system in the United States is the National Childhood Vaccine Injury Act. This legislation was intended to bolster vaccine research and development through federal coordination of vaccine initiatives, and by providing relief to vaccine manufacturers facing financial burdens. A key component of the legislation required the Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse effects, especially in children.
The Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health effects associated with specific vaccines covered by the Vaccine Injury Compensation Program including varicella zoster vaccine, influenza vaccines, hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews prior studies, summarizes their findings, and evaluates the epidemiological evidence. It finds that while no vaccine is 100% safe, very few adverse events are shown to be caused by vaccines.
In addition, the evidence shows that vaccines do not cause several conditions of recent concern. For example, the MMR vaccine is not associated with autism or childhood diabetes. The DTaP vaccine is also not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. The Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.Contents note:
SUMMARY 1 -- Charge to the Committee 2 -- Assessing the Weight of Evidence 2 -- Causality Assessment 5 -- Causality Conclusions 7 -- Susceptibility 9 -- Concluding Comment 9 -- References 24 -- 1 INTRODUCTION 25 -- Charge to the Committee 27 -- Committee Process 28 -- Outline of the Report 28 -- References 33 -- 2 APPROACH 35 -- Literature Searching 35 -- Weight of Evidence 36 -- Causality Assessment 41 -- Special Considerations 45 -- References 48 -- 3 EVALUATING BIOLOGICAL MECHANISMS OF ADVERSE EVENTS 51 -- Latency Between Antigen Exposure and Peak Adaptive Immune Response 51 -- Immune-Mediated Mechanisms 52 -- Viral Activity 66 -- Injection-Related Adverse Events 67 -- Coagulation and Hypercoagulable States 69 -- Increased Susceptibility 70 -- Alterations in Brain Development 73 -- Contribution of Animal Models 76 -- References 79 -- 4 MEASLES, MUMPS, AND RUBELLA VACCINE 89 -- Introduction 89 -- Measles Inclusion Body Encephalitis 93 -- Encephalitis and Encephalopathy 95 -- Febrile Seizures 100 -- Afebrile Seizures 105 -- Meningitis 107 -- Ataxia 110 -- Autism 112 -- Acute Disseminated Encephalomyelitis 115 -- Transverse Myelitis 116 -- Optic Neuritis 117 -- Neuromyelitis Optica 119 -- Multiple Sclerosis Onset in Adults 120 -- Multiple Sclerosis Onset in Children 122 -- Guillain-Barré Syndrome 123 -- Chronic Inflammatory Disseminated Polyneuropathy 124 -- Opsoclonus Myoclonus Syndrome 125 -- Brachial Neuritis 125 -- Anaphylaxis 126 -- Transient Arthralgia in Women 130 -- Transient Arthralgia in Children 134 -- Chronic Arthralgia in Women 137 -- Chronic Arthritis in Women 140 -- Chronic Arthropathy in Children 143 -- Arthropathy in Men 144 -- Type 1 Diabetes 146 -- Hepatitis 149 -- Chronic Fatigue Syndrome 150 -- Fibromyalgia 151 -- Hearing Loss 151 -- References 196 -- 5 VARICELLA VIRUS VACCINE 211 -- Introduction 211 -- Disseminated Oka VZV Without Other Organ Involvement 213 -- Disseminated Oka VZV with Other Organ Involvement 219 -- Vaccine Strain Viral Reactivation Without Other Organ Involvement 224 -- Vaccine Strain Viral Reactivation with Other Organ Involvement 228 -- Encephalopathy 233 -- Seizures 233 -- Cerebellar Ataxia 235 -- Acute Disseminated Encephalomyelitis 236 -- Transverse Myelitis 237 -- Guillain-Barré Syndrome 238 -- Small Fiber Neuropathy 239 -- Anaphylaxis 239 -- Onset or Exacerbation of Arthropathy 242 -- Stroke 243 -- Thrombocytopenia 244 -- References 248 -- 6 INFLUENZA VACCINE 257 -- Introduction 257 -- Encephalitis and Encephalopathy 262 -- Seizures 264 -- Acute Disseminated Encephalomyelitis 267 -- Optic Neuritis 269 -- Neuromyelitis Optica 271 -- Multiple Sclerosis Onset in Adults 271 -- Multiple Sclerosis Relapse in Adults 273 -- Guillain-Barré Syndrome 275 -- Chronic Inflammatory Disseminated Polyneuropathy 281 -- Bells Palsy 282 -- Brachial Neuritis 284 -- Small Fiber Neuropathy 285 -- Anaphylaxis 285 -- Inactivated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children and Adults 288 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children Younger Than 5 Years of Age 293 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Persons 5 Years of Age or Older 298 -- Onset or Exacerbation of Systemic Lupus Erythematosus 301 -- Onset or Exacerbation of Vasculitis 304 -- Polyarteritis Nodosa 306 -- Onset or Exacerbation of Arthropathy 307 -- Stroke 308 -- Myocardial Infarction 309 -- Fibromyalgia 311 -- All-Cause Mortality 311 -- Oculorespiratory Syndrome 313 -- References 354 -- 7 HEPATITIS A VACCINE 369 -- Introduction 369 -- Acute Disseminated Encephalomyelitis 370 -- Transverse Myelitis 371 -- Multiple Sclerosis 372 -- Guillain-Barré Syndrome 373 -- Chronic Inflammatory Disseminated Polyneuropathy 374 -- Bells Palsy 374 -- Anaphylaxis 375 -- Autoimmune Hepatitis 376 -- References 378 -- 8 HEPATITIS B VACCINE 381 -- Introduction 381 -- Encephalitis and Encephalopathy 383 -- Seizures 383 -- Acute Disseminated Encephalomyelitis 385 -- Transverse Myelitis 386 -- Optic Neuritis 387 -- Neuromyelitis Optica 389 -- Multiple Sclerosis Onset in Adults 390 -- Multiple Sclerosis Onset in Children 392 -- Multiple Sclerosis Relapse in Adults 394 -- Multiple Sclerosis Relapse in Children 395 -- First Demyelinating Event in Adults 396 -- First Demyelinating Event in Children 399 -- Guillain-Barré Syndrome 400 -- Chronic Inflammatory Disseminated Polyneuropathy 401 -- Brachial Neuritis 402 -- Anaphylaxis 402 -- Erythema Nodosum 403 -- Onset or Exacerbation of Systemic Lupus Erythematosus 404 -- Onset or Exacerbation of Vasculitis 406 -- Onset or Exacerbation of Polyarteritis Nodosa 409 -- Onset or Exacerbation of Psoriatic Arthritis 411 -- Onset or Exacerbation of Reactive Arthritis 412 -- Onset or Exacerbation of Rheumatoid Arthritis 414 -- Onset or Exacerbation of Juvenile Idiopathic Arthritis 416 -- Type 1 Diabetes 418 -- Fibromyalgia 420 -- References 431 -- 9 HUMAN PAPILLOMAVIRUS VACCINE 441 -- Introduction 441 -- Acute Disseminated Encephalomyelitis 442 -- Transverse Myelitis 443 -- Neuromyelitis Optica 444 -- Multiple Sclerosis 444 -- Guillain-Barré Syndrome 445 -- Chronic Inflammatory Disseminated Polyneuropathy 446 -- Brachial Neuritis 447 -- Amyotrophic Lateral Sclerosis 447 -- Anaphylaxis 449 -- Transient Arthralgia 450 -- Pancreatitis 451 -- Thromboembolic Events 452 -- Hypercoagulable States 453 -- References 455 -- 10 DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND ACELLULAR PERTUSSISCONTAINING -- VACCINES 457 -- Introduction 457 -- Encephalitis and Encephalopathy 461 -- Infantile Spasms 464 -- Seizures 465 -- Ataxia 468 -- Autism 468 -- Acute Disseminated Encephalomyelitis 469 -- Transverse Myelitis 470 -- Optic Neuritis 471 -- Multiple Sclerosis Onset in Adults 472 -- Multiple Sclerosis Relapse in Adults 474 -- Multiple Sclerosis Relapse in Children 476 -- Guillain-Barré Syndrome 477 -- Chronic Inflammatory Disseminated Polyneuropathy 478 -- Opsoclonus Myoclonus Syndrome 480 -- Bells Palsy 480 -- Anaphylaxis 482 -- Chronic Urticaria 483 -- Serum Sickness 484 -- Arthropathy 485 -- Type 1 Diabetes 487 -- Myocarditis 490 -- Fibromyalgia 491 -- Sudden Infant Death Syndrome 491 -- Immune Thrombocytopenic Purpura 492 -- References 506 -- 11 MENINGOCOCCAL VACCINE 515 -- Introduction 515 -- Encephalitis and Encephalopathy 517 -- Acute Disseminated Encephalomyelitis 518 -- Transverse Myelitis 519 -- Multiple Sclerosis 519 -- Guillain-Barré Syndrome 520 -- Chronic Inflammatory Disseminated Polyneuropathy 521 -- Anaphylaxis 522 -- Chronic Headache 523 -- References 526 -- 12 INJECTION-RELATED ADVERSE EVENTS 529 -- Complex Regional Pain Syndrome 529 -- Deltoid Bursitis 531 -- Syncope 533 -- References 538 -- 13 CONCLUDING COMMENTS 541 -- References 545Link for e-copy: http://www.nap.edu/catalog.php?record_id=13164 Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2712 Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium / Adriaan Blommaert in Vaccine, 32(2014)46 ([10/21/2014])
![]()
[article] Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium [printed text] / Adriaan Blommaert, Author ; J Bilcke, Author ; Yannick Vandendijck, Author ; Germaine Hanquet, Author ; Niel Hens, Author ; Philippe Beutels, Author . - 2014 . - 6075-6083.
Languages : English (eng)
in Vaccine > 32(2014)46 [10/21/2014] . - 6075-6083
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
2010-02-2 ; Belgium ; Health Personnel ; Influenza Vaccines ; Journal Article ; Models, Econometric ; Peer Review ; R204 ; RiskAbstract: Risk groups with increased vulnerability for influenza complications such as pregnant women, persons with underlying illnesses as well as persons who come into contact with them, such as health care workers, are currently given priority (along with other classic target groups) to receive seasonal influenza vaccination in Belgium. We aimed to evaluate this policy from a health care payer perspective by cost-effectiveness analysis in the three specific target groups above, while accounting for effects beyond the target group. Increasing the coverage of influenza vaccination is likely to be cost-effective for pregnant women (median euro6589 per quality-adjusted life-year (QALY) gained [euro4073-euro10,249]) and health care workers (median euro24,096/QALY gained [euro16,442-euro36,342]), if this can be achieved without incurring additional administration costs. Assuming an additional physician's consult is charged to administer each additional vaccine dose, the cost-effectiveness of vaccinating pregnant women depends strongly on the extent of its impact on the neonate's health. For health care workers, the assumed number of preventable secondary infections has a strong influence on the cost-effectiveness. Vaccinating people with underlying illnesses is likely highly cost-effective above 50 years of age and borderline cost-effective for younger persons, depending on relative life expectancy and vaccine efficacy in this risk group compared to the general population. The case-fatality ratios of the target group, of the secondary affected groups and vaccine efficacy are key sources of uncertainty. Link for e-copy: http://dx.doi.org/10.1016/j.vaccine.2014.08.085 Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3701 [article]Seasonal influenza vaccination: prioritizing children or other target groups? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
Seasonal influenza vaccination: prioritizing children or other target groups? : Estimation of influenza attributable admissions and deaths: a regression analysis Supplement 2 [printed text] / Philippe Beutels, Author ; Yannick Vandendijck, Author ; Lander Willem, Author ; Nele Goeyvaerts, Author ; Adriaan Blommaert, Author ; Kim van Kerckhove, Author ; J Bilcke, Author ; Germaine Hanquet, Author ; P. Neels, Author ; Nancy Thiry, Author ; Jori Liesenborgs, Author ; Niel Hens, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2013 . - 85 p. : Ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 204S2) .
ISSN : D/2013/10.273/47 : 0,00
Study 2010-02 HTA VZV Vaccination
Languages : English (eng)
Descriptors: Indexation
2010-02-2 ; Adolescent ; Aged ; Child ; Child, Preschool ; Comorbidity ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Health Personnel ; Infant ; Influenza Vaccines ; Influenza, Human ; Middle Aged ; Pregnancy ; R204 ; Young Adult
Classification
WC 515 Human influenzaContents note: SUPPLEMENT REPORT 1 -- 1. SUMMARY 8 -- 1.1. BACKGROUND AND METHOD 8 -- 1.2. PREDICTION OF INFLUENZA ATTRIBUTABLE ADMISSIONS 9 -- 1.3. PREDICTION OF INFLUENZA ATTRIBUTABLE DEATHS 11 -- 1.4. CONCLUSIONS 12 -- 2. BACKGROUND 13 -- 3. METHODS AND DATA SOURCES 14 -- 3.1. PARAMETERS CONSIDERED IN REGRESSION 14 -- 3.2. SELECTION OF REGRESSION MODELS 15 -- 3.3. ANALYSIS OF RESIDUALS 15 -- 4. DESCRIPTION OF BASELINE PARAMETERS 16 -- 5. SELECTION OF MODELS 19 -- 5.1. SELECTION OF MODEL DISTRIBUTION AND LINK 19 -- 5.2. COMPARING NEGATIVE BINOMIAL AND OVER-DISPERSED POISSON 19 -- 5.3. SELECTION OF FINAL MODELS 22 -- 6. ANALYSIS OF P+I ADMISSIONS 23 -- 6.1. P+I ADMISSIONS AS PRINCIPAL DIAGNOSIS 23 -- 6.1.1. Selection of models 23 -- 6.1.2. Findings of final models 29 -- 6.1.3. Predicted influenza attributable admissions 30 -- 6.2. ANALYSIS OF P+I ADMISSIONS AS ANY DIAGNOSIS 33 -- 6.2.1. Selection of models 33 -- 6.2.2. Findings of final models 33 -- 6.2.3. Predicted influenza attributable admissions 35 -- 6.3. ANALYSIS BASED ON ALL RESPIRATORY AND CIRCULATORY ADMISSIONS 36 -- 6.3.1. Description of data 36 -- 6.3.2. Selection of models and model findings 37 -- 6.3.3. Predicted influenza attributable admissions 38 -- 7. ANALYSIS OF P+I DEATHS 40 -- 7.1. ANALYSIS OF P+I DEATHS AS PRINCIPAL CAUSE 40 -- 7.1.1. Selection of models 40 -- 7.1.2. Findings of final models 42 -- 7.1.3. Predicted influenza attributable deaths 42 -- 7.2. ANALYSIS OF P+I DEATHS AS ANY CAUSE 45 -- 7.2.1. Selection of models 45 -- 7.2.2. Findings of final models 47 -- 7.2.3. Predicted influenza attributable deaths 48 -- 8. SUMMARY OF RESULTS AND COMPARISON WITH OTHER STUDIES 51 -- 8.1. COMPARISON OF INFLUENZA ATTRIBUTABLE ADMISSIONS 52 -- 8.2. COMPARISON OF INFLUENZA ATTRIBUTABLE DEATHS 55 -- 9. CONCLUSIONS AND DISCUSSION 56 -- APPENDICE: FURTHER DETAILS ON REGRESSION RESULTS 58 -- 1. COMPARING DIFFERENT DISTRIBUTIONS, ADMISSIONS 58 -- 1.1. COMPARISON SUMMARY 58 -- 1.2. MODEL FITTING OF NEGATIVE BINOMIAL, MAIN MODEL 60 -- 1.3. MODEL FITTING OF OVER-DISPERSED POISSON REGRESSION 62 -- 1.4. STANDARD (GAUSSIAN) REGRESSION FOR ADMISSIONS 65 -- 2. MODELS FITS AND AUTO-CORRELOGRAMS OF DIFFERENT MODELS 68 -- 2.1. MODEL 1, P+I ADMISSION AS PRINCIPAL DIAGNOSIS 68 -- 2.2. MODEL 2, P+I ADMISSION AS MAIN DIAGNOSIS 71 -- 2.3. MODEL 1, P+I ADMISSION AS ANY DIAGNOSIS 74 -- 2.4. MODEL 2, P+I ADMISSION AS ANY DIAGNOSIS 77 -- 2.5. P+I DEATHS AS PRINCIPAL CAUSE 80 -- 3. ADDITIONAL DATA ON INFLUENZA ATTRIBUTABLE DEATHS 82 -- 3.1. P+I DEATHS AS MAIN CAUSE 82 -- 3.2. ATTRIBUTABLE INFLUENZA DEATHS BY AGE, P+I AS MAIN CAUSE 83 -- REFERENCE LIST 84 Link for e-copy: http://doi.org/10.57598/R204S2 Format of e-copy: PDF (947 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3239 Copies
Barcode Call number Media type Location Section Status No copy Seasonal influenza vaccination: prioritizing children or other target groups? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
Seasonal influenza vaccination: prioritizing children or other target groups? : Part II: cost-effectiveness analysis [printed text] / Philippe Beutels, Author ; Yannick Vandendijck, Author ; Lander Willem, Author ; Nele Goeyvaerts, Author ; Adriaan Blommaert, Author ; Kim van Kerckhove, Author ; J Bilcke, Author ; Germaine Hanquet, Author ; P. Neels, Author ; Nancy Thiry, Author ; Jori Liesenborgs, Author ; Niel Hens, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2013 . - 247 p. : Ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 204C) .
ISSN : D/2013/10.273/43 : 0,00
Study 2010-02 HTA VZV Vaccination
Languages : English (eng)
Descriptors: Indexation
2010-02-2 ; Adolescent ; Aged ; Child ; Child, Preschool ; Comorbidity ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Health Personnel ; Infant ; Influenza Vaccines ; Influenza, Human ; Middle Aged ; Pregnancy ; R204 ; Young Adult
Classification
WC 515 Human influenzaContents note: SCIENTIFIC REPORT 16 -- 1 BACKGROUND 16 -- 2 OBJECTIVES 18 -- 3 EVIDENCE REVIEWS 18 -- 3.1 VACCINE EFFICACY AND EFFECTIVENESS 18 -- 3.1.1 Methods 18 -- 3.1.2 Influenza vaccine efficacy in children. 20 -- 3.1.3 Influenza vaccine efficacy in healthy adults 25 -- 3.1.4 Influenza vaccine efficacy/effectiveness in the elderly 26 -- 3.1.5 Influenza vaccine efficacy/effectiveness in the persons ≤65 years with co-morbidities 29 -- 3.2 VACCINE SAFETY 30 -- 3.2.1 Influenza vaccines safety in children 30 -- 3.2.2 Influenza vaccines safety in adults 31 -- 3.2.3 Special potential issues for influenza vaccine safety 33 -- 3.3 ECONOMIC EVALUATIONS 34 -- 3.3.1 Childhood vaccination options 34 -- 3.3.2 Adult vaccination options 40 -- 3.4 DYNAMIC TRANSMISSION MODELS 44 -- 3.4.1 Search strategy 44 -- 3.4.2 Results 45 -- 3.5 QUALITY OF LIFE 54 -- 3.5.1 Search strategy 54 -- 3.5.2 Results 54 -- 4 DATA COLLECTION AND INTERMEDIARY ANALYSES 59 -- 4.1 EPIDEMIOLOGICAL AND BURDEN OF DISEASE DATA 59 -- 4.1.1 ILI and influenza surveillance, hospitalization rates and deaths 59 -- 4.1.2 Estimation of influenza related admissions and deaths through regression analyses 59 -- 4.2 COST DATA 65 -- 4.2.1 Out of hospital costs for Influenza Like Illness (ILI) and clinically diagnosed influenza 65 -- 4.2.2 In-hospital costs for hospitalised influenza patients 76 -- 5 METHODS 80 -- 5.1 OPTIONS FOR VACCINATION 80 -- 5.1.1 Using the dynamic transmission model 80 -- 5.1.2 Using the static models 81 -- 5.2 DESCRIPTION OF THE DYNAMIC TRANSMISSION MODEL 81 -- 5.2.1 Model structure 81 -- 5.2.2 Fundamental differences between our and Vynnycky et als approach 87 -- 5.2.3 Dynamic model parameter imputation by fitting to past observations 89 -- 5.3 DESCRIPTION OF THE STATIC MODELS 97 -- 5.4 ANALYTICAL APPROACH TO ECONOMIC EVALUATION 97 -- 5.5 PARAMETER VALUES AND DISTRIBUTIONS 99 -- 5.5.1 Parameters for dynamic transmission model-based projections 99 -- 5.5.2 Parameters for static model-based projections 105 -- 6 RESULTS 119 -- 6.1 OPTIONS CONSIDERED WITH THE DYNAMIC TRANSMISSION MODEL 119 -- 6.1.1 Modified children options + current adult vaccination 119 -- 6.1.2 Current children vaccination + modified adult vaccination targets 132 -- 6.1.3 Modified children options + modified adult vaccination targets 140 -- 6.1.4 Modified children options + modified adult vaccination reduction 156 -- 6.1.5 Sensitivity analyses 166 -- 6.2 OPTIONS CONSIDERED WITH THE STATIC MODELS 208 -- 6.2.1 Vaccinating pregnant women 208 -- 6.2.2 Vaccinating health care workers (HCWs) 212 -- 6.2.3 Vaccinating people with comorbidities 220 -- 7 SUMMARY AND DISCUSSION 225 -- 7.1 VACCINATING CHILDREN 225 -- 7.2 CHANGING COVERAGE IN ADULTS WITH OR WITHOUT CHILDHOOD VACCINATION 227 -- 7.3 LIMITATIONS OF THE STUDY 227 -- 7.4 FUTURE PERSPECTIVES 228 -- REFERENCES 230 Link for e-copy: http://doi.org/10.57598/R204C Format of e-copy: PDF (5,5 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3234 Copies
Barcode Call number Media type Location Section Status No copy Seasonal influenza vaccination: prioritizing children or other target groups? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
Seasonal influenza vaccination: prioritizing children or other target groups? : Part II: cost-effectiveness analysis - Supplement [printed text] / Philippe Beutels, Author ; Yannick Vandendijck, Author ; Lander Willem, Author ; Nele Goeyvaerts, Author ; Adriaan Blommaert, Author ; Kim van Kerckhove, Author ; J Bilcke, Author ; Germaine Hanquet, Author ; P. Neels, Author ; Nancy Thiry, Author ; Jori Liesenborgs, Author ; Niel Hens, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2013 . - 111 p. : Ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 204S1v1) .
ISSN : D/2013/10.273/44 : 0,00
Study 2010-02 HTA VZV Vaccination
Languages : English (eng)
Descriptors: Indexation
2010-02-2 ; Adolescent ; Aged ; Child ; Child, Preschool ; Comorbidity ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Health Personnel ; Infant ; Influenza Vaccines ; Influenza, Human ; Middle Aged ; Pregnancy ; R204 ; Young Adult
Classification
WC 515 Human influenzaContents note: 1. REVIEW DETAILS OF EFFICACY AND EFFECTIVENESS STUDIES 7 -- 1.1. INFLUENZA VACCINE EFFICACY IN CHILDREN 7 -- 1.1.1. Live Attenuated Influenza Vaccine (LAIV) studies in children based on EPAR 7 -- 1.1.2. Published data on LAIV & TIV in children 15 -- 1.2. INFLUENZA VACCINE EFFICACY IN HEALTHY ADULTS 21 -- 2. SELECTION OF QUALITY OF LIFE STUDIES FOR REVIEW 24 -- 2.1. SEARCH STRATEGY FOR QUALITY OF LIFE STUDIES 24 -- 2.2. CATEGORISATION AND SELECTION OF QUALITY OF LIFE STUDIES 25 -- 3. COST DATA 27 -- 3.1. LIST OF COMORBIDITIES COMBINED WITH A DIAGNOSIS OF INFLUENZA 27 -- 3.2. LIST OF PREGNANCY COMPLICATIONS 30 -- 3.3. IN-HOSPITAL COSTS FOR HOSPITALIZED INFLUENZA PATIENTS 37 -- 3.3.1. Aggregated data on in-hospital cost for hospitalised influenza patients 37 -- 3.3.2. Disaggregated data on in-hospital cost for hospitalised influenza patients 63 Link for e-copy: http://doi.org/10.57598/R204S1.1 Format of e-copy: PDF (4,6 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3236 Copies
Barcode Call number Media type Location Section Status No copy Seasonal influenza vaccination: prioritizing children or other target groups? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
PermalinkSeasonal influenza vaccination: prioritizing children or other target groups? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
PermalinkSeasonal influenza vaccination: prioritizing children or other target groups? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
PermalinkSeasonal influenza vaccination / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
PermalinkVaccinatie tegen seizoensinfluenza: prioritair de kinderen of andere doelgroepen? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
PermalinkVaccinatie tegen seizoensinfluenza / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
PermalinkVaccination contre la grippe saisonnière / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
PermalinkVaccination contre la grippe saisonnière : priorité aux enfants ou à dautres groupes cibles ? / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)
![]()
Permalink
